ClinicalTrials.gg
CompletedNCT01889069Updated Aug 13, 2020Results posted

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)

A Phase 3 interventional study of Rituximab and Cyclophosphamide in Lymphoma, sponsored by Hoffmann-La Roche. Completed at 39 sites in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-08-13.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
159
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 253 studies testing rituximab in Lymphoma — 11 open to participants now, 17 under way, 2 of them phase 3. Rituximab · Lymphoma.

Enrollment
28th of 237
159 · median 44
Started
2013
with 6 others
Phase 3
26 of 253
1 open now
Registered
216th of 253
by date

Among the 253 studies testing rituximab in Lymphoma, this one is the 28th largest by enrollment of the 237 interventional ones that give a count, is one of 7 that started in 2013, is one of 26 in phase 3, and was the 216th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

11 of the 253 studies testing rituximab in Lymphoma are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies testing rituximab in Lymphoma, or all of them as a file.
02

Study summary

This single arm, multicenter study will evaluate the safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab in previously untreated participants with cluster of differentiation 20 positive (CD20+) DLBCL or FL. In addition to standard chemotherapy, participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period.

03

Conditions studied

  • Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, CD20+ DLBCL or CD20+ follicular non-Hodgkin's lymphoma (NHL) Grade 1, 2 or 3a, according to the World Health Organization (WHO) classification system
  • Currently being treated with rituximab intravenously (IV) in the Induction or Maintenance period, having received at least one full dose of rituximab IV, defined as standard full dose of rituximab IV 375 milligrams per square-meter (mg/m\^2) administered without interruption or early discontinuation (i.e. tolerability issues)
  • Expectation and current ability for the participant to receive at least 4 additional cycles of treatment during the Induction period or 6 additional cycles of treatment during the Maintenance period (participants with follicular NHL)
  • An International Prognostic Index (IPI) score of 1-4 or IPI score of 0 with bulky disease, defined as one lesion greater than or equal to (>=) 7.5 centimeters (cm), or Follicular Lymphoma International Prognostic Index (FLIPI) (low, intermediate or high risk) assessed before the first rituximab IV administration in Induction period
  • At least one bi-dimensionally defined as >=1.5 cm in its largest dimension on computed tomography (CT) scan
  • (ECOG) performance status less than or equal to (\<=) 3

Exclusion criteria

Exclusion Criteria:

  • Transformed lymphoma or FL IIIB
  • Primary central nervous system lymphoma, histologic evidence of transformation to a Burkitt lymphoma, primary effusion lymphoma, primary mediastinal DLBCL, DLBCL of the testis, or primary cutaneous DLBCL
  • History of other
  • Ongoing use greater than (>) 30 milligrams per day (mg/day) of prednisone or equivalent
  • Inadequate renal, hematologic, or hepatic function
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
  • to any of the individual components of standard chemotherapy
  • Other serious underlying medical conditions, which, in the Investigator's judgement, could impair the ability of the participant to participate in the study
  • Recent major surgery (within 4 weeks prior to dosing, other than for diagnosis)
  • Active virus (HBV), active virus (HCV) infection, or (HIV) infection
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Rituximab

    Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.

    Drug: Rituximab · Drug: Cyclophosphamide · Drug: Vincristine · Drug: Doxorubicin · Drug: Prednisone · Drug: Bendamustine

Interventions

  • Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.

    Also known as: MabThera, Rituxan

  • Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.

  • Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.

  • Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.

  • Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.

  • Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Administration-Associated Reactions (AAR)

    AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.

    Time frame: Baseline up to 54 months

Secondary outcomes

  1. Percentage of Participants With At Least One Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs)

    An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the CTCAE, version 4.0.

    Time frame: Baseline up to 54 months

  2. Percentage of Participants With At Least One Grade ≥ 3 Infusion/ Injection Related Reactions (IIRRs)

    Grading of IIRRs was completed according to the CTCAE, version 4.0.

    Time frame: Baseline up to 54 months

  3. Percentage of Participants With At Least One Treatment-Emergent Serious Adverse Events

    SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.

    Time frame: Baseline up to 54 months

  4. Percentage of Participants With Event-Free Survival (EFS) According to IWG Response Criteria

    EFS was defined as the time from first dose of rituximab to first occurrence of progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurred first.

    Time frame: Day 1 up to first occurrence of progression or relapse, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first (up to maximum 54 months)

  5. Percentage of Participants With Progression-Free Survival (PFS) According to IWG Response Criteria

    PFS was defined as the time from first dose of rituximab to the first occurrence of disease progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or death from any cause, whichever occurred first.

    Time frame: Day 1 up to first occurrence of progression or relapse, or death, whichever occurs first (up to maximum 54 months)

  6. Percentage of Participants With Overall Survival (OS)

    OS was defined as the time from first dose of rituximab to death from any cause.

    Time frame: Day 1 until death (up to maximum 54 months)

  7. Percentage of Participants With Disease-Free Survival (DFS) According to IWG Response Criteria

    DFS assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occured first.

    Time frame: From 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occurs first (up to maximum 54 months) (end of Induction period = up to 8 months)

  8. Percentage of Participants With Complete Response (CR) According to IWG Response Criteria

    Complete response required: 1) the complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities, 2) all lymph nodes and nodal masses had regressed to normal size, 3) the spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and not be palpable on physical examination and 4) if the bone marrow was involved by lymphoma before treatment, the infiltrate was cleared on repeat bone marrow aspirate and biopsy of the same site. CR/unconfirmed (CRu) included those patients who fulfilled criteria 1 and 3 above as well as 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that regressed by more than 75% in the SPD and 2) indeterminate bone marrow. Response was assessed according to the IWG response criteria.

    Time frame: At 4 to 8 weeks after end of Induction period (end of Induction period = up to 8 months)

  9. FL: Plasma Trough Concentrations of Rituximab

    FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Pharmacokinetic (PK) data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.

    Time frame: Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1

  10. FL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab

    FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.

    Time frame: Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1

  11. FL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)

    FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.

    Time frame: Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1

  12. DLBCL: Plasma Concentrations of Rituximab

    DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

    Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

  13. DLBCL: Plasma Trough Concentrations of Rituximab

    DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

    Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 pre-dose on Day 1

  14. DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab

    DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

    Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

  15. DLBCL: Maximum Plasma Concentration (Cmax) of Rituximab

    DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

    Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

  16. DLBCL: Apparent Total Clearance (CL/F) of Rituximab

    DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

    Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

  17. DLBCL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)

    DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

    Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

  18. DLBCL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab

    DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

    Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

  19. DLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21

    Plasma concentrations of rituximab in participants with DLBCL by chemotherapy regimen cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 14 days (R-CHOP-14) or cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 21 days (R-CHOP-21) in the PK) population.DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

    Time frame: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1

  20. Rituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores

    Patient-assessed satisfaction was evaluated using RASQ. Participants were asked questions regarding convenience and satisfaction for rituximab SC. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. DLBCL participants could be enrolled at cycle 2, cycle 3, or cycle 4. FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must be able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Each Cycle is 21 days for DLBCL. Each Cycle 21 days during the Induction phase and 2 months during Maintenance phase for FL.

    Time frame: DLBCL: Cycle (C) 2, C3, C4, C5, C6, End of C8; FL: Induction: C3, C4, C5, C6, C8, Maintenance: C2, C3, C4, C5, C6, C7, C8, C10, C12, End of treatment (4-8 weeks after last dose)

07

Results

Posted Aug 13, 2020

Participant flow

The study was conducted at 37 investigational centers in Italy.

Participant flow — Overall Study
MilestoneSubcutaneous (SC) Rituximab
Started158
Completed113
Not completed45
Withdrew: Death18
Withdrew: Progression of disease14
Withdrew: Lost to follow-up6
Withdrew: Other4
Withdrew: Consent withdrawal3

Outcome measures

PrimaryPercentage of Participants With Administration-Associated Reactions (AAR)

AARs were defined as all adverse events (AEs) occurring within 24 hours of rituximab administration and which were considered related to study drug. AARs included infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof. Grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.

Time frame:
Baseline up to 54 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Administration-Associated Reactions (AAR)
Percentage of ParticipantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous (SC) Rituximab
At least One AAR4.28.16.3
At Least One AAR Grade ≥3000
Cutaneous and Soft Tissue AARs (Localized)1.48.15.1
Cutaneous and Soft Tissue AARs (Non-Localized)2.801.3
SecondaryPercentage of Participants With At Least One Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with the treatment. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the CTCAE, version 4.0.

Time frame:
Baseline up to 54 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With At Least One Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs)
Percentage of ParticipantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous (SC) Rituximab
Percentage of Participants With At Least One Grade ≥ 3 Treatment-Emergent Adverse Events (TEAEs)51.443.046.8
SecondaryPercentage of Participants With At Least One Grade ≥ 3 Infusion/ Injection Related Reactions (IIRRs)

Grading of IIRRs was completed according to the CTCAE, version 4.0.

Time frame:
Baseline up to 54 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With At Least One Grade ≥ 3 Infusion/ Injection Related Reactions (IIRRs)
Percentage of ParticipantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous (SC) Rituximab
Percentage of Participants With At Least One Grade ≥ 3 Infusion/ Injection Related Reactions (IIRRs)000
SecondaryPercentage of Participants With At Least One Treatment-Emergent Serious Adverse Events

SAE was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/ birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.

Time frame:
Baseline up to 54 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With At Least One Treatment-Emergent Serious Adverse Events
Percentage of ParticipantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous (SC) Rituximab
Percentage of Participants With At Least One Treatment-Emergent Serious Adverse Events36.126.731.0
SecondaryPercentage of Participants With Event-Free Survival (EFS) According to IWG Response Criteria

EFS was defined as the time from first dose of rituximab to first occurrence of progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurred first.

Time frame:
Day 1 up to first occurrence of progression or relapse, or initiation of a non-protocol-specified anti-lymphoma therapy or death, whichever occurs first (up to maximum 54 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Event-Free Survival (EFS) According to IWG Response Criteria
Percentage of ParticipantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous (SC) Rituximab
Percentage of Participants With Event-Free Survival (EFS) According to IWG Response Criteria29.222.125.3
SecondaryPercentage of Participants With Progression-Free Survival (PFS) According to IWG Response Criteria

PFS was defined as the time from first dose of rituximab to the first occurrence of disease progression or relapse, according to the International Working Group (IWG) response criteria or other country standards, or death from any cause, whichever occurred first.

Time frame:
Day 1 up to first occurrence of progression or relapse, or death, whichever occurs first (up to maximum 54 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Progression-Free Survival (PFS) According to IWG Response Criteria
Percentage of ParticipantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous (SC) Rituximab
Percentage of Participants With Progression-Free Survival (PFS) According to IWG Response Criteria29.222.125.3
SecondaryPercentage of Participants With Overall Survival (OS)

OS was defined as the time from first dose of rituximab to death from any cause.

Time frame:
Day 1 until death (up to maximum 54 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Overall Survival (OS)
Percentage of ParticipantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous (SC) Rituximab
Percentage of Participants With Overall Survival (OS)19.44.711.4
SecondaryPercentage of Participants With Disease-Free Survival (DFS) According to IWG Response Criteria

DFS assessed in participants achieving complete response (CR) including complete response unconfirmed (Cru) and was defined as the period from 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occured first.

Time frame:
From 4 to 8 weeks after end of Induction period up to relapse or death from any cause, whichever occurs first (up to maximum 54 months) (end of Induction period = up to 8 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Disease-Free Survival (DFS) According to IWG Response Criteria
Percentage of ParticipantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous (SC) Rituximab
Percentage of Participants With Disease-Free Survival (DFS) According to IWG Response Criteria21.725.623.5
SecondaryPercentage of Participants With Complete Response (CR) According to IWG Response Criteria

Complete response required: 1) the complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normalization of those biochemical abnormalities, 2) all lymph nodes and nodal masses had regressed to normal size, 3) the spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and not be palpable on physical examination and 4) if the bone marrow was involved by lymphoma before treatment, the infiltrate was cleared on repeat bone marrow aspirate and biopsy of the same site. CR/unconfirmed (CRu) included those patients who fulfilled criteria 1 and 3 above as well as 1) a residual lymph node mass greater than 1.5 cm in greatest transverse diameter that regressed by more than 75% in the SPD and 2) indeterminate bone marrow. Response was assessed according to the IWG response criteria.

Time frame:
At 4 to 8 weeks after end of Induction period (end of Induction period = up to 8 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Complete Response (CR) According to IWG Response Criteria
Percentage of ParticipantsDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Subcutaneous (SC) Rituximab
Percentage of Participants With Complete Response (CR) According to IWG Response Criteria65.2 (52.4 to 76.5)67.9 (53.7 to 80.1)66.4 (57.2 to 74.8)
SecondaryFL: Plasma Trough Concentrations of Rituximab

FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Pharmacokinetic (PK) data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.

Time frame:
Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1
Reported as:
Mean · micrograms per millilitre (ug/mL)
FL: Plasma Trough Concentrations of Rituximab
micrograms per millilitre (ug/mL)Follicular Lymphoma (FL)
Cycle 2 Predose55.49 ± 64.275
Cycle 3 Predose119.50 ± 139.606
Cycle 4 Predose157.25 ± 132.583
Cycle 5 Predose7.60 ± NA
Baseline90.88 ± 107.089
Cycle 8 Predose201.56 ± 372.609
SecondaryFL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab

FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.

Time frame:
Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1
Reported as:
Geometric least squares mean · micrograms per millilitre (ug/mL)
FL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab
micrograms per millilitre (ug/mL)Follicular Lymphoma (FL)
FL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab61.01 (42.49 to 87.61)
SecondaryFL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)

FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. PK data only collected for participants enrolled during Induction. During the induction phase each Cycle is 21 days.

Time frame:
Induction collection: Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, and Cycle 8 Predose on Day 1
Reported as:
Mean · micrograms per millilitre (ug/mL)
FL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)
micrograms per millilitre (ug/mL)Follicular Lymphoma (FL)
Cycle 2 Predose48.86 ± 57.640
Cycle 3 Predose156.33 ± 193.753
Cycle 4 Predose200.33 ± 123.411
Cycle 5 Predose7.60 ± NA
Baseline97.90 ± 118.897
Cycle 8 Predose284.08 ± 504.113
SecondaryDLBCL: Plasma Concentrations of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

Time frame:
Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
Reported as:
Mean · micrograms per millilitre (ug/mL)
DLBCL: Plasma Concentrations of Rituximab
micrograms per millilitre (ug/mL)Diffuse Large B-Cell Lymphoma (DLBCL)
Cycle 2 Predose42.53 ± 49.637
Cycle 3 Predose88.92 ± 92.790
Cycle 4 Predose110.50 ± 101.116
Cycle 5 Predose100.20 ± 44.483
Baseline92.92 ± 114.466
Cycle 7 Predose141.44 ± 122.314
Cycle 7 Day 7348.81 ± 490.785
Cycle 7 Day 14226.40 ± 136.729
Cycle 8 Predose117.61 ± 89.394
SecondaryDLBCL: Plasma Trough Concentrations of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

Time frame:
Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 pre-dose on Day 1
Reported as:
Mean · micrograms per millilitre (ug/mL)
DLBCL: Plasma Trough Concentrations of Rituximab
micrograms per millilitre (ug/mL)Diffuse Large B-Cell Lymphoma (DLBCL)
Cycle 2 Predose42.53 ± 49.637
Cycle 3 Predose88.92 ± 92.790
Cycle 4 Predose110.50 ± 101.116
Cycle 5 Predose100.20 ± 44.483
Baseline92.92 ± 114.466
Cycle 7 Predose141.44 ± 122.314
Cycle 8 Predose117.61 ± 89.394
SecondaryDLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

Time frame:
Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
Reported as:
Mean · mcg*hr/mL
DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of Rituximab
mcg*hr/mLDiffuse Large B-Cell Lymphoma (DLBCL)
DLBCL: Area Under the Plasma Concentration-Time Curve (AUC) of RituximabNA ± NA
SecondaryDLBCL: Maximum Plasma Concentration (Cmax) of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

Time frame:
Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
Reported as:
Mean · micrograms per millilitre (ug/mL)
DLBCL: Maximum Plasma Concentration (Cmax) of Rituximab
micrograms per millilitre (ug/mL)Diffuse Large B-Cell Lymphoma (DLBCL)
DLBCL: Maximum Plasma Concentration (Cmax) of RituximabNA ± NA
SecondaryDLBCL: Apparent Total Clearance (CL/F) of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

Time frame:
Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
Reported as:
Mean · liter per hour (L/h)
DLBCL: Apparent Total Clearance (CL/F) of Rituximab
liter per hour (L/h)Diffuse Large B-Cell Lymphoma (DLBCL)
DLBCL: Apparent Total Clearance (CL/F) of RituximabNA ± NA
SecondaryDLBCL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

Time frame:
Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
Reported as:
Mean · micrograms per millilitre (ug/mL)
DLBCL: Plasma Trough Concentrations of Rituximab in Participants With Complete Response/Complete Response Unconfirmed (CR/CRu)
micrograms per millilitre (ug/mL)Diffuse Large B-Cell Lymphoma (DLBCL)
Cycle 2 Predose53.97 ± 56.169
Cycle 3 Predose101.79 ± 101.223
Cycle 4 Predose110.50 ± 101.116
Cycle 5 Predose121.67 ± 45.092
Baseline109.40 ± 125.603
Cycle 7 Predose157.93 ± 131.178
Cycle 8 Predose132.57 ± 95.447
SecondaryDLBCL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab

DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

Time frame:
Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
Reported as:
Geometric least squares mean · micrograms per millilitre (ug/mL)
DLBCL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab
micrograms per millilitre (ug/mL)Diffuse Large B-Cell Lymphoma (DLBCL)
DLBCL: Overall Geometric Least Square (LS) Mean Plasma Trough Concentrations of Rituximab70.50 (57.60 to 86.28)
SecondaryDLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21

Plasma concentrations of rituximab in participants with DLBCL by chemotherapy regimen cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 14 days (R-CHOP-14) or cyclophosphamide, oncovine (vincristine), doxorubicin, prednisone/prednisolone given every 21 days (R-CHOP-21) in the PK) population.DLBCL participants received at least 1 infusion of rituximab and must have been able to receive at least 4 cycles of rituximab SC; therefore DLBCL participants could be enrolled at Cycle 2, Cycle 3, Cycle 4, or Cycle 5 and as a result the baseline PK sample could be collected at Cycle 2, Cycle 3, Cycle 4, or Cycle 5. Each Cycle is 21 days.

Time frame:
Cycle 2 Predose, Cycle 3 Predose, Cycle 4 Predose, Cycle 5 Predose, Baseline Predose, Cycle 7 Predose on Day 1, Cycle 7 Day 7, Cycle 7 Day 14, Cycle 8 Predose on Day 1
Reported as:
Mean · micrograms per millilitre (ug/mL)
DLBCL: Plasma Concentrations During Different Scheduling of Rituximab SC R-CHOP-14 or R-CHOP-21
micrograms per millilitre (ug/mL)Diffuse Large B-Cell Lymphoma (DLBCL) R-CHOP-14Diffuse Large B-Cell Lymphoma (DLBCL) R-CHOP-21
Cycle 2 Predose170.00 ± NA28.37 ± 22.695
Cycle 3 Predose—88.92 ± 92.790
Cycle 4 Predose—110.50 ± 101.116
Cycle 5 Predose125.00 ± NA94.00 ± 48.806
Baseline214.25 ± 233.49374.25 ± 77.064
Cycle 7 Predose93.50 ± 79.903150.13 ± 126.221
Cycle 7 Day 771.55 ± 26.092398.76 ± 517.974
Cycle 7 Day 1442.00 ± NA272.50 ± 103.722
Cycle 8 Predose78.50 ± 14.849123.76 ± 92.606
SecondaryRituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores

Patient-assessed satisfaction was evaluated using RASQ. Participants were asked questions regarding convenience and satisfaction for rituximab SC. Each domain is scored on a scale of 0 to 100, with higher scores indicative of more positive feelings toward therapy. The score for each domain was averaged among all participants. DLBCL participants could be enrolled at cycle 2, cycle 3, or cycle 4. FL participants could be enrolled during induction or maintenance phase and they should have received at least 1 infusion of rituximab and must be able to receive at least 4 cycles of rituximab SC if enrolled during induction or 4 cycles of rituximab SC if enrolled during maintenance. Each Cycle is 21 days for DLBCL. Each Cycle 21 days during the Induction phase and 2 months during Maintenance phase for FL.

Time frame:
DLBCL: Cycle (C) 2, C3, C4, C5, C6, End of C8; FL: Induction: C3, C4, C5, C6, C8, Maintenance: C2, C3, C4, C5, C6, C7, C8, C10, C12, End of treatment (4-8 weeks after last dose)
Reported as:
Mean · Units on a Scale
Rituximab Administration Satisfaction Questionnaire (RASQ) Convenience and Satisfaction Domain Scores
Units on a ScaleDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)
Convenience domain Cycle 3 Induction—81.8 ± 8.66
Convenience domain Cycle 4 Induction—76.5 ± 6.26
Convenience domain Cycle 5 Induction—79.6 ± 10.30
Convenience domain Cycle 6 Induction—95.8 ± 5.89
Convenience domain Cycle 8 Induction—83.1 ± 9.18
Convenience domain Cycle 2 Treatment75.0 ± NA—
Convenience domain Cycle 3 Treatment81.9 ± 10.28—
Convenience domain Cycle 4 Treatment82.1 ± 12.17—
Convenience domain Cycle 5 Treatment83.3 ± 9.96—
Convenience domain Cycle 6 Treatment80.8 ± 9.85—
Convenience domain Cycle 8 Treatment83.8 ± 11.60—
Convenience domain Cycle 2 Maintenance—83.6 ± 8.71
Convenience domain Cycle 3 Maintenance—87.5 ± 19.54
Convenience domain Cycle 4 Maintenance—100.0 ± 0.00
Convenience domain Cycle 5 Maintenance—80.2 ± 12.55
Convenience domain Cycle 6 Maintenance—83.3 ± 16.67
Convenience domain Cycle 7 Maintenance—82.7 ± 12.59
Convenience domain Cycle 8 Maintenance—93.8 ± 12.50
Convenience domain Cycle 10 Maintenance—91.7 ± NA
Convenience domain Cycle 12 Maintenance—86.3 ± 12.69
Convenience domain End of Treatment—75.0 ± 16.67
Satisfaction domain Cycle 3 Induction—89.4 ± 10.23
Satisfaction domain Cycle 4 Induction—84.1 ± 13.80
Satisfaction domain Cycle 5 Induction—91.7 ± 8.84
Satisfaction domain Cycle 6 Induction—93.8 ± 8.84
Satisfaction domain Cycle 8 Induction—91.3 ± 9.47
Satisfaction domain Cycle 2 Treatment87.5 ± NA—
Satisfaction domain Cycle 3 Treatment83.3 ± 11.53—
Satisfaction domain Cycle 4 Treatment85.6 ± 13.62—
Satisfaction domain Cycle 5 Treatment83.3 ± 8.84—
Satisfaction domain Cycle 6 Treatment84.6 ± 14.57—
Satisfaction domain Cycle 8 Treatment91.2 ± 12.76—
Satisfaction domain Cycle 2 Maintenance—92.0 ± 9.28
Satisfaction domain Cycle 3 Maintenance—79.2 ± 20.41
Satisfaction domain Cycle 4 Maintenance—100.0 ± NA
Satisfaction domain Cycle 5 Maintenance—79.7 ± 16.28
Satisfaction domain Cycle 6 Maintenance—87.5 ± 17.68
Satisfaction domain Cycle 7 Maintenance—94.2 ± 9.00
Satisfaction domain Cycle 8 Maintenance—93.8 ± 7.22
Satisfaction domain Cycle 10 Maintenance—50.0 ± NA
Satisfaction domain Cycle 12 Maintenance—91.0 ± 13.21
Satisfaction domain End of Treatment—75.0 ± 21.65

Adverse events

Collected over Baseline up to 54 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diffuse Large B-Cell Lymphoma (DLBCL)14/72 (19.4%)26/72 (36.1%)50/72 (69.4%)
Follicular Lymphoma (FL)4/86 (4.7%)23/86 (26.7%)56/86 (65.1%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)
NeutropeniaBlood and lymphatic system disorders15/7213/86
Neutrophil Count DecreasedInvestigations5/721/86
Febrile NeutropeniaBlood and lymphatic system disorders4/722/86
PneumoniaInfections and infestations2/720/86
White Blood Cell Count DecreasedInvestigations2/720/86
LymphopeniaBlood and lymphatic system disorders0/722/86
ThrombocytopeniaBlood and lymphatic system disorders0/722/86
Cholecystitis AcuteHepatobiliary disorders0/722/86
CholelithiasisHepatobiliary disorders0/722/86
LeukopeniaBlood and lymphatic system disorders1/721/86
Most frequent other events
Showing 10 of 19
Most frequent other events
EventDiffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)
NeutropeniaBlood and lymphatic system disorders21/7220/86
AstheniaGeneral disorders14/723/86
PyrexiaGeneral disorders11/7215/86
CoughRespiratory, thoracic and mediastinal disorders6/7215/86
AnaemiaBlood and lymphatic system disorders11/726/86
Neutrophil Count DecreasedInvestigations9/721/86
ParaesthesiaNervous system disorders9/727/86
Influenza Like IllnessGeneral disorders2/729/86
DiarrhoeaGastrointestinal disorders7/727/86
LeukopeniaBlood and lymphatic system disorders2/727/86

Baseline characteristics

ITT population included all enrolled participants. All analyses described have been performed by type of lymphoma (DLBCL/ FL) and overall. Total overall participants enrolled in the study was 159, however for the subject disposition and baseline characteristics the enrolled was 158 as one participant discontinued the study prior to treatment.

Age, Continuous
Age, Continuous(years)Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Total
Intent-to-Treat Population59.7 ± 12.7057.8 ± 9.9258.7 ± 11.28
Sex: Female, Male
Sex: Female, Male(Participants)Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Total
Female284472
Male444286
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma (FL)Total
Hispanic or Latino459
Not Hispanic or Latino5972131
Unknown or Not Reported9918
08

Study locations

39 sites
  • Irccs Crob
    Rionero in Vulture, Basilicata 85028, Italy
  • Azienda Ospedaliera Bianchi-Melacrino-Morelli; Unità Operativa di Ematologia
    Reggio Calabria, Calabria 89100, Italy
  • Azienda Ospedaliera S.G. Moscati; Divisione Ematologia
    Avellino, Campania 83100, Italy
  • Asl ce - p.o. Avers; Uoc ematologia
    Aversa, Campania 81031, Italy
  • A.O. San Sebastiano; U.O.C. Oncologia
    Caserta, Campania 81100, Italy
  • Seconda università degli studi di napoli; Medicina clinica e sperimentale magrassi - lanzara
    Napoli, Campania 80138, Italy
  • Osp. Santa Maria Goretti; Ematologia
    Latina, Lazio 04100, Italy
  • Ospedale S. Eugenio; Divisione Di Ematologia
    Roma, Lazio 00144, Italy
  • Regina Elena National Cancer Institute; Hematology
    Roma, Lazio 00144, Italy
  • Az. Osp. S. Camillo Forlanini; Uo Ematologia E Trapianti Di Midollo Osseo
    Roma, Lazio 00152, Italy
  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol
    Roma, Lazio 00161, Italy
  • Azienda Ospedaliera S. Giovanni Addolorata; UOC Ematologia
    Roma, Lazio 00184, Italy
  • ASL Viterbo; Presidio Ospedaliero di Ronciglione; UOC Ematologia
    Ronciglione, Lazio 01037, Italy
  • Ospedale Valduce;U.O.S. Oncologia Ed Ematologia
    Como, Lombardia 22100, Italy
  • ASST DI CREMA; U O Oncologia Medica
    Crema, Lombardia 26013, Italy
  • ASST DI LECCO; Oncologia Medica
    Lecco, Lombardia 23900, Italy
  • Az. Osp. Carlo Poma; Divisione Di Oncologia Medica
    Mantova, Lombardia 46100, Italy
  • Osp. San Raffaele; Dip. Di Oncoematologia
    Milano, Lombardia 20132, Italy
  • Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico
    Milano, Lombardia 20133, Italy
  • Irccs Policlinico San Matteo; Divisione Di Ematologia
    Pavia, Lombardia 27100, Italy
  • Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
    Rozzano, Lombardia 20089, Italy
  • Ospedale Gen.Le Prov.Le 'C.G.Mazzoni'; Ematologia
    Ascoli Piceno, Marche 63100, Italy
  • Ospedale di Civitanova Marche; Medicina Interna
    Civitanova Marche, Marche 62012, Italy
  • Ospedale di Macerata; Medicina Generale
    Macerata, Marche 62100, Italy
  • Università Cattolica Del Sacro Cuore S.S. Giovanni Paolo Ii; Uoc Di Onco-Ematologia
    Campobasso, Molise 86100, Italy
  • Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia
    Alessandria, Piemonte 15121, Italy
  • Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.& Ircad
    Novara, Piemonte 28100, Italy
  • Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
    Bari, Puglia 70124, Italy
  • Azienda ospedaliera oo rr di foggi; Hematology
    Foggia, Puglia 71100, Italy
  • Ospedale Roberto Binaghi; Centro trapianti di midollo osseo
    Cagliari, Sardegna 09126, Italy
  • Osp. San Francesco; Ematologia e CTMO
    Nuoro, Sardegna 08100, Italy
  • ARNAS Garibaldi; Ematologia
    Catania, Sicilia 95122, Italy
  • Az. Osp. Papardo; Struttura Complessa Di Ematologia
    Messina, Sicilia 98165, Italy
  • ARNAS-Ospedale Civico Maurizio Ascoli; Unità Operativa di Oncologia Medica
    Palermo, Sicilia 90127, Italy
  • Azienda Uni Ria Policlinico P. Giaccone ; Divisione Di Ematologia E Trapianto
    Palermo, Sicilia 90127, Italy
  • Ospedale Santa Chiara; Unita Operativa Di Ematologia
    Pisa, Toscana 56100, Italy
  • USL 4 di Prato - Nuovo Ospeale di Prato
    Prato, Toscana 59100, Italy
  • A.O. Santa Maria Terni; S.C. Oncoematologia
    Terni, Umbria 05100, Italy
  • IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
    Padova, Veneto 35128, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in May 2019, 69 months.

Results were first posted in Aug 2020, 1 year 2 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's 69 months is above that.

Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2013
First posted
Jun 28, 2013
StartActual
Jul 31, 2013
Primary completionActual
May 28, 2019
CompletionActual
May 28, 2019
Results first posted
Aug 13, 2020
Last update
Aug 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01889069
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 28, 2013
Start date
Jul 31, 2013
Primary completion
May 28, 2019
Completion
May 28, 2019
Results posted
Aug 13, 2020
Last update
Aug 13, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion